A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Thrombosis Research

Background:

• Thrombolytic therapies carry a risk of systemic hemorrhage due to non-specific clot lysis.
• Existing treatments struggle to differentiate between pathological and hemostatic clots.

Purpose of the Study:

• To develop a targeted plasmin-based thrombolytic nanocage.
• To achieve efficient clot dissolution without systemic fibrinolysis or disruption of hemostatic clots.

Main Methods:

• Engineered a double-chambered short-length ferritin (sFt) construct.
• Fused N-terminal with clot-targeting peptides (CLT) and C-terminal with microplasmin (μPn).
• Assembled CLT-sFt-μPn into a nanocage structure to protect activated μPn.

Main Results:

• The CLT-sFt-μPn nanocage demonstrated enhanced stability and prolonged circulatory half-life compared to free μPn.
• Successfully lysed pre-existing arterial and venous clots in thrombosis models.
• Showed targeted activity, minimizing systemic fibrinolytic effects.

Conclusions:

• The CLT-sFt-μPn thrombolytic nanocage platform is a promising prototype for targeted clot dissolution.
• This approach offers improved efficacy and safety over conventional thrombolytic agents.
• Represents a significant advancement in the treatment of thrombotic diseases.